SCHAUMBURG, Ill., Sept. 30 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. According to IMS, 2008 sales of vinorelbine injection, USP in the United States approximated $17 million. Sagent will begin marketing and shipping vinorelbine injection immediately.
"Sagent has launched six products in the third quarter of 2009, including vinorelbine, our third oncolytic product. Our innovative business model enables us to provide our customers with a broad range of products and delivery systems with features designed to help enhance safety and convenience," said Michael Logerfo, corporate vice president of Sagent. "We continue to receive positive feedback from our customers who often consider the enhanced features of our products to be important factors when making their purchasing decisions."
Sagent's vinorelbine injection is offered in 10 mg per 1 mL and 50 mg per 5 mL, latex-free and preservative-free, single-dose vials that incorporate easy-to-read product and dosage information.
About Vinorelbine Injection, USP
Vinorelbine injection is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, vinorelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, vinorelbine is indicated in combination with cisplatin.
The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, boxed warnings and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developi
|SOURCE Sagent Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved